A software tool for organ-specific second cancer risk assessment from exposure to therapeutic doses

Eleftherios Tzanis, Michael Mazonakis, John Damilakis

Department of Medical Physics, Medical School, University of Crete, Heraklion, Crete, Greece

ABSTRACT

The aim of this study was the development of a software tool (ScRcalc) for the automatic estimation of the patient- and organ-specific cancer risk due to radiotherapy. ScRcalc was developed using the Python 3.8.7 programming language. It incorporates equations and parameters of mechanistic models for the calculation of the organ equivalent dose (OED), the excess absolute risk (EAR) and the lifetime attributable risk (LAR) of carcinogenesis for various organs due to radiotherapy. Data from differential dose-volume histograms, as defined by a treatment planning system, could be automatically inserted into the program. Eighteen different cancer risk estimates for various organs were performed of patients subjected to radiation therapy with conventional and modulated techniques. These software estimates were compared with manual calculations. ScRcalc was developed as a standalone executable program without any dependencies. It enables direct estimations of the OED and LAR for various organs at risk. An important aspect of the software is that it does not require pre-processing of the DVH data. No differences were found between the ScRcalc results and those derived from manual calculations. The newly developed software offers the possibility to medical physicists and radiation oncologists to directly estimate the probability of radiotherapy-induced secondary malignancies for various organs at risk.

Key words: radiotherapy; radiation risk assessment; secondary malignancies; Python, software development

Rep Pract Oncol Radiother 2022;27(1):170–175

Introduction

The cancer death rate has been continuously reduced since 1991 leading to an overall decrease of 29% nowadays [1]. The advances in anticancer treatment have contributed to the above drop of the mortality rate [1]. Radiation therapy remains one of the main modalities for the management of several malignant diseases. However, the exposure of a cancer patient to high doses of ionizing radiation may lead to the development of a secondary malignant neoplasm [2]. The use of modern modulated irradiation techniques which involve extended treatment times and expose a larger volume of healthy tissues compared to conventional radiotherapy may further increase the second cancer risk [2, 3].

The risk of developing radiotherapy-induced malignancies has been extensively determined on the basis of epidemiological data [4, 5]. The collection of these data requires the follow-up of irradiated patients for a very long time taking into account that the latency for the development of solid tumors is more than 10 years and reaches 60 years [6]. Leukemia appears in a period of 15 years following radiation exposure [6]. Linear and non-linear models may provide the required data for estimating the probability of cancer incidence following exposure to ionizing radiation. Linear
models suggest the direct proportion of the cancer risk and radiation dose [7, 8]. This linearity is presented up to radiation doses of about 2.5 Gy [3]. The linear relationship between dose and risk is not evident for the high doses delivered during radiotherapy [9]. Several non-linear models have already been applied for the assessment of the second cancer risk to organs exposed to high therapeutic doses [10–13]. These mathematical models involve the use of equations and/or parameters making their application sometimes difficult and time-consuming in clinical practice. Moreover, some of these approaches ignore the impact either of the target dose fractionation during the entire treatment course or of the cell repopulation in the probability of subsequent carcinogenesis [10, 11, 14, 15].

The purpose of this study was to develop a software tool for the automatic estimation of the patient- and organ-specific cancer risk due to external-beam radiotherapy, on the basis of treatment planning data, a non-linear model [16], accounting for cell killing, tumor dose fractionation and tissue proliferation, and a bell-shaped model [17].

**Materials and Methods**

**Model-based cancer risk estimates**

Almost 50% of the radiotherapy-induced secondary malignancies are presented in organs located in the margin area of the treatment volume [18]. The radiation dose to these structures is inhomogeneously distributed and portions of the organs receive therapeutic doses of more than 2 Gy. The linearity between the radiation dose and the risk of carcinogenesis is in dispute for the above high doses [3]. The probability of carcinogenesis in these heavily exposed organs can be calculated with a non-linear mechanistic model proposed by Schneider et al. [16]. This model has been defined from the combined Japanese A-bomb and Hodgkin cohorts. The model is based on the calculation of the organ equivalent dose (OED) using differential dose volume histograms (DVH) obtained by the treatment planning system as follows:

\[
OED = \frac{1}{V_T} \sum_i V_i \frac{\exp(-a'_i D_i)}{a'_i R} \left[ 1 - 2 R + R^2 \exp(a'_i D_i) - \frac{(1 - R)\exp\left(-\frac{a'_i R}{1 - R} D_i\right)}{(1 - R)^2} \right] \tag{1}
\]

where \(V_T\) is the total organ volume, \(V_i\) is the volume of the organ at risk (OAR) absorbing a radiation dose of \(D_i\), \(R\) is the organ-dependent repair parameter and \(a'_i\) is an organ-specific factor related to the cell killing. The \(a'_i\) is given by the equation:

\[
a'_i = a + \frac{\beta D_i}{n} \tag{2}
\]

where \(a\) and \(\beta\) are parameters from the linear-quadratic model and \(n\) is the number of fractions.

The mechanistic model proposed by Schneider et al. [16] allows calculation of the OED for the lungs, rectum, stomach, fem-breast, bladder, liver, esophagus, colon, brain-cns, salivary gland, mouth-pharynx and small intestine. The thyroid gland was excluded from the analysis of Schneider et al. [15]. The bell-shaped model as previously described [17] was used for calculating the OED of the thyroid as follows:

\[
OED_{\text{thyroid}} = \frac{1}{V_T} \sum_i V_i D_i \exp(-a'_i D_i) \tag{3}
\]

The OED is required for estimating the organ-specific excess absolute risk (EAR) for second cancer induction after radiotherapy as follows:

\[
EAR = \beta_{\text{EAR}} \frac{\text{OED}}{\text{OED}} \exp\left[\gamma_{a}(A_e - 30) + \gamma_{a}\ln\left(\frac{A_e}{70}\right)\right] \tag{4}
\]

where \(\beta_{\text{EAR}}\) is the slope of the dose-response curve at low doses, \(A_e\) is the patient’s age during irradiation, \(A_a\) is the attained patient’s age and \(\gamma_a\) and \(\gamma_e\) are the age modifying factors. The parameters in the equations (1), (2) and (3) were taken from the literature [16, 19]. The sum of the EARs up to the maximum attained age \((Age_{\text{max}})\) provides the site-specific lifetime attributable risk (LAR) of carcinogenesis:

\[
LAR = \sum_{A_{\text{max}}} \left[ \text{EAR}\left(A_{\text{max}} A_a S_{\text{i}}\right) \frac{S_{\text{i}}}{S_{\text{e}}} \right] \tag{5}
\]

where \(L\) is a cancer risk free interval of 5 years and \(S_i/S_e\) is the probability of a healthy person to survive from \(A_e\) to \(A_a\) as obtained by the U.S. life tables [20].

**Algorithm and graphical user interface (GUI) development**

SCRcalc was developed using the Python 3.8.7 programming language. The Python script consists of three sections. The first section incorporates thirteen callable functions. Each function returns the
parameters $\beta_0, \gamma_e, \gamma_a, \alpha, \beta$ and $R$ for a specific OAR. Moreover, this section included two lists with the male and female surviving probabilities as obtained by the U.S. life tables [20]. The second section of the script is the computational part of the algorithm. The callable functions integrated in this section calculate the OED, $a'$, EAR as well as the LAR through equations 1, 2, 4 and 5, respectively. For thyroid, the algorithm calculates the OED through equation 3. The algorithm was developed to derive $D_i$ and $V_i$ values from the differential dose-volume histogram (DVH) text file which is exported from the treatment planning software. The third section of the script incorporates the code for the development of the graphical user interface (GUI). The mathematical calculations are assessed using the math module while for the development of the GUI the tkinter module was employed. The final script was compiled to a standalone executable program.

The SCRcalc’s GUI consists of three windows as Figure 1 indicatively shows. In the first window the user selects the preferable OAR. Following the selection of the organ, the second window appears, and the user imports the age of the patient during the treatment period, the attained age, the number of fractions as well as the DVH text file. Pre-processing of the DVH text file is not required. Thus, the user can export the DVH text file from the treatment planning software and directly import it into the SCRcalc software. Finally, by selecting the gender of the patient, the third window appears, presenting the calculated values of the OED and LAR. The software offers the option of saving the report as a text file by clicking the Print Report button (Fig. 2).

**Patients**

The newly developed software was employed to estimate the second cancer risks for nine patients subjected to radiotherapy for several malignancies. The patients’ age and gender and the applied treatment parameters are presented in Table 1. The left breast and supraclavicular lymph nodes of patient no. 3 were treated. For patient no. 6, 50.4 Gy were given to the pelvic lymph nodes while the prostate received a simultaneous integrated boost to 67.2 Gy. The treatment plans were created with the Monaco system (Elekta AB, Stockholm, Sweden) for use in an Infinity linear accelerator (Elekta AB, Stockholm, Sweden) generating 6 MV photons. The two partial or full arcs rotated in opposite directions in all volumetric modulated arc therapy (VMAT) plans. Differential DVHs showing the dose distribution of the partially in-field organs were inserted into the software environment for estimating the organ-specific cancer risk. The software-based estimations were compared with the risks derived from manual calculations.

![Figure 1](https://journals.viamedica.pl/rpor)
Results and Discussion

In the current study, 18 different OED and LAR calculations were carried out using the SCRcalc for various critical organs of patients irradiated with 3-dimensional conformal radiation therapy (3D-CRT), intensity modulated radiation therapy (IMRT) or VMAT. Table 2 presents the calculated values. The OED values were found to be 0.2–10.7 Gy. The LAR varied from 0.03% to 8.39% by the OAR and the treatment site. These values were also calculated manually to confirm the accuracy of the software. No differences were found between the above OEDs and LARs with those derived from manual calculations.

The manual cancer risk assessment is a time-consuming task based on the processing of DVH data and the implementation of a set of complex equations. Different formulas should be predefined for each OAR using the proper organ-dependent parameters. SCRcalc software enables direct estimations of the OED and LAR for various organs at risk. An important aspect of the software is that it does not require pre-processing of the DVH data. The user should import the DVH text file to the SCRcalc without any pre-processing, define patient’s age and gender to obtain OED and LAR values in seconds. Moreover, the software was developed as a standalone executable program without any dependencies. It can be installed to any workstation and its use does not require programming skills. This offers the possibility to medical physicists and radiation oncologists to directly estimate the probability of radiotherapy-induced secondary malignancies for various organs at risk.

Secondary malignant neoplasms usually occur either inside the primary radiation field or in the

Table 1. Patients’ age and gender and the applied treatment parameters

| Patient | Gender | Age* (years) | Primary disease         | Target dose [Gy] | No. fractions | RT technique | Fields/Arcs  |
|---------|--------|--------------|-------------------------|------------------|---------------|--------------|--------------|
| 1       | Male   | 57           | Graves orbitopathy      | 20               | 10            | 3D-CRT       | 2 lateral fields  |
| 2       | Male   | 59           | Laryngeal cancer        | 70               | 35            | VMAT         | 2 partial arcs   |
| 3       | Female | 50           | Left breast cancer      | 50               | 25            | IMRT         | 7 fields      |
| 4       | Male   | 64           | Stomach cancer          | 45               | 25            | VMAT         | 2 full arcs    |
| 5       | Female | 61           | Endometrial cancer      | 45               | 25            | VMAT         | 2 full arcs    |
| 6       | Male   | 67           | Prostate cancer         | 67               | 28            | VMAT         | 2 full arcs    |
| 7       | Female | 52           | Rectal cancer           | 50               | 28            | 3D-CRT       | 4 field box   |
| 8       | Male   | 44           | Testicular cancer       | 20               | 10            | 3D-CRT       | AP-PA         |
| 9       | Female | 49           | Cervical cancer         | 50               | 28            | IMRT         | 7 fields      |

*Age* refers to the age of patient during radiotherapy; 3D-CRT — 3-dimensional conformal radiation therapy; VMAT — volumetric modulated arc therapy; IMRT — intensity modulated radiation therapy

Figure 2. The user has the option to save the report as a text file with the Print Report button. Here, the results and report of patient 3 esophagus are presented.
Reports of Practical Oncology and Radiotherapy 2022, vol. 27, no. 1

Diallo et al. [21] found that 78% of the secondary tumors in the examined irradiated cancer survivors appeared in the aforementioned regions. Welte et al. [22] reported that 69% of the second malignancies in their cohort were positioned within the primarily irradiated volume and at the field margins. Berrington de Gonzalez et al. [23] also found that 54% of the radiotherapy-induced tumors occurred at sites located at distances smaller than 3 cm from the field borders. These sites received high radiation doses exceeding 5 Gy.

The proposed tool can be applied in clinical practice whenever the second cancer risk needs to be estimated for critical organs which are entirely or partly encompassed by the radiotherapy fields. The use of the software is limited to the following organs with high predilection for radiation carcinogenesis: lungs, rectum, stomach, fem-breast, bladder, liver, esophagus, colon, brain-cns, salivary gland, mouth-pharynx, small intestine and thyroid. For each of the above organs, Schneider et al. [16] provided the required parameters for calculating the OED and LAR values. It should be mentioned that the LAR estimates contain a lot of uncertainty due to errors in the definition of the organ-specific model parameters. Furthermore, the software cannot be used for cancer risk assessment to distant sites from the treatment volume exposed to low doses due to secondary radiation. Different computational or measurement methods should be used for estimating the out-of-field organ doses and radiogenic risks [24, 25].

### Conclusion

SCRcalc is a newly developed software tool for the automatic estimation of the patient- and organ-specific cancer risk due to radiotherapy. The software’s GUI is self-explanatory and no programming skills are required from the user. SCRcalc offers the possibility to radiation oncologists and medical physicists to compare the radiation-induced cancer risks for various organs at risk from different radiotherapy treatment techniques and choose the option with the minimum risk for each patient. As no pre-processing of the DVH data is required, and the calculations are performed in seconds, the evaluation of the radiotherapy treatment plans can be implemented in every-day clinical practice with minimum added workload.

### Conflict of interest

None declared.

### Funding

None declared.

### Acknowledgements

None declared.

### References

1. Siegel RL, Miller KD, Goding Sauer A, et al. Cancer statistics, 2020. CA Cancer J Clin. 2020; 70(1): 7–30, doi: 10.3322/caac.21590, indexed in Pubmed: 31912902.

2. Kamran SC, Berrington de Gonzalez A, Ng A, et al. Therapeutic radiation and the potential risk of second malignancies. Cancer. 2016; 122(12): 1809–1821, doi: 10.1002/cncr.29841, indexed in Pubmed: 26950597.

3. Hall EJ. Intensity-modulated radiation therapy, protons, and the risk of second cancers. Int J Radiat Oncol Biol Phys. 2006; 65(1): 1–7, doi: 10.1016/j.ijrobp.2006.01.027, indexed in Pubmed: 16618572.

4. Grantzau T, Overgaard J. Risk of second non-breast cancer among patients treated with and without postoperative radiotherapy for primary breast cancer: A systematic review and meta-analysis of population-based studies including 522,739 patients. Radiother Oncol. 2016; 121(3): table 2. Calculated organ equivalent dose (OED) and lifetime attributable risk (LAR) values

| Patient | Organ          | OED [Gy] | LAR (%) |
|---------|----------------|----------|---------|
| 1       | Brain          | 0.928    | 0.052   |
| 2       | Thyroid        | 3.751    | 0.054   |
| 3       | Esophagus      | 0.901    | 0.579   |
|         | Contralateral Breast | 2.342 | 1.927   |
|         | Ipsilateral Lung | 5.013 | 8.385   |
| 4       | Ipsilateral Lung | 0.580 | 0.183   |
| 5       | Liver          | 0.740    | 0.102   |
| 6       | Bladder        | 0.226    | 0.057   |
|         | Rectum         | 9.774    | 0.223   |
| 7       | Bladder        | 0.204    | 0.027   |
|         | Rectum         | 10.720   | 0.123   |
| 8       | Small intestine | 0.245 | 0.145   |
|         | Bladder        | 0.765    | 0.337   |
| 9       | Stomach        | 0.541    | 0.602   |
|         | Colon          | 4.011    | 2.534   |
|         | Liver          | 0.520    | 0.185   |
| 10      | Bladder        | 0.636    | 0.323   |
|         | Rectum         | 0.494    | 0.026   |
Eleftherios Tzanis et al. Second cancer risk assessment in radiotherapy

402–413, doi: 10.1016/j.radonc.2016.08.017, indexed in Pubmed: 27639892.

5. Chaturvedi AK, Engels EA, Gilbert ES, et al. Second cancers among 104,760 survivors of cervical cancer: evaluation of long-term risk. J Natl Cancer Inst. 2007; 99(21): 1634–1643, doi: 10.1093/jnci/djm201, indexed in Pubmed: 17971527.

6. Hall EJ, Giaccia AJ. Radiobiology for the radiologist 7th edn. Lippincott Williams and Wilkins. Philadelphia 2012.

7. ICRP. The 2007 Recommendations of the International Commission on Radiological Protection. ICRP publication 103. Ann ICRP. 2007; 37: 9–34.

8. National Research Council. Health Risks from Exposure to Low Levels of Ionizing Radiation: BEIR VII Phase 2. National Academies Press, Washington 2006.

9. Harrison R. Out-of-field doses in radiotherapy: Input to epidemiological studies and dose-risk models. Phys Med. 2017; 42: 239–246, doi: 10.1016/j.ejmp.2017.02.001, indexed in Pubmed: 28392312.

10. Dasu A, Tomà-Dasu I. Dose-effect model for risk-relationship to cell survival parameters. Acta Oncol. 2005; 44(8): 829–35, doi: 10.1080/02841860500401159, indexed in Pubmed: 16332590.

11. Shuryak I, Hahnfeldt P, Hlatky L, et al. A new view of radiation-induced cancer: integrating short- and long-term processes. Part II: second cancer risk estimation. Radiat Environ Biophys. 2009; 48(3): 275–286, doi: 10.1007/s00411-009-0231-2, indexed in Pubmed: 19499238.

12. Schneider U. Modeling the risk of secondary malignancies after radiotherapy. Genes (Basel). 2011; 2(4): 1033–1049, doi: 10.3390/genes2041033, indexed in Pubmed: 24710304.

13. Sachs RK, Brenner DJ. Solid tumor risks after high doses of ionizing radiation. Proc Natl Acad Sci U S A. 2005; 102(37): 13040–13045, doi: 10.1073/pnas.0506648102, indexed in Pubmed: 16150705.

14. Dasu A, Tomà-Dasu I. Models for the risk of secondary cancers from radiotherapy. Phys Med. 2017; 42: 232–238, doi: 10.1016/j.ejmp.2017.02.015, indexed in Pubmed: 28242139.

15. Schneider U. Modeling the risk of secondary malignancies after radiotherapy. Genes (Basel). 2011; 2(4): 1033–1049, doi: 10.3390/genes2041033, indexed in Pubmed: 24710304.

16. Schneider U, Sumila M, Robotka J. Site-specific dose-response relationships for cancer induction from the combined Japanese A-bomb and Hodgkin cohorts for doses relevant to radiotherapy. Theor Biol Med Model. 2011; 8: 27, doi: 10.1186/1742-4682-8-27, indexed in Pubmed: 21791103.

17. Murray L, Sethugavalar B, Robertshaw H, et al. Involved Node, Site, Field and Residual Volume Radiotherapy for Lymphoma: A Comparison of Organ at Risk Dosimetry and Second Malignancy Risks. Clin Oncol (RC Coll Radiol). 2015; 27(7): 401–410, doi: 10.1016/j.clon.2015.03.005, indexed in Pubmed: 25840609.

18. Dörr W, Herrmann T. Second primary tumors after radiotherapy for malignancies. Treatment-related parameters. Strahlenther Onkol. 2002; 178(7): 357–362, doi: 10.1007/s00066-002-0951-6, indexed in Pubmed: 12163989.

19. Murray L, Sethugavalar B, Robertshaw H, et al. Involved Node, Site, Field and Residual Volume Radiotherapy for Lymphoma: A Comparison of Organ at Risk Dosimetry and Second Malignancy Risks. Clin Oncol (RC Coll Radiol). 2015; 27(7): 401–410, doi: 10.1016/j.clon.2015.03.005, indexed in Pubmed: 25840609.

20. Arias E. United States Life Tables, 2017. Natl Vital Stat Rep. 2019; 68(7): 1–66, indexed in Pubmed: 32501200.

21. Diallo I, Haddy N, Adjadj E, et al. Frequency distribution of second solid cancer locations in relation to the irradiated volume among 115 patients treated for childhood cancer. Int J Radiat Oncol Biol Phys. 2009; 74(3): 876–883, doi: 10.1016/j.ijrobp.2009.01.040, indexed in Pubmed: 19386434.

22. Welte B, Suhr P, Bottke D, et al. Second malignancies in high-dose areas of previous tumor radiotherapy. Strahlenther Onkol. 2010; 186(3): 174–179, doi: 10.1007/s00066-010-2050-4, indexed in Pubmed: 20339826.

23. Gonzalez Ade, Curtis R, Kry S, et al. Proportion of second cancers attributable to radiotherapy treatment in adults: a cohort study in the US SEER cancer registries. Lancet Oncol. 2011; 12(4): 353–360, doi: 10.1016/s1470-2045(11)70064-6, indexed in Pubmed: 21454129.

24. Mazonakis M, Kourinou K, Lyra R, et al. Thyroid exposure to scattered radiation and associated radiogenic risks from paediatric radiotherapy for extracranial tumours. Radiat Prot Dosimetry. 2012; 152(4): 317–322, doi: 10.1093/rpd/ncs056, indexed in Pubmed: 22504308.

25. Mazonakis M, Berris T, Varveris C, et al. Out-of-field organ doses and associated radiogenic risks from para-aortic radiotherapy for testicular seminoma. Med Phys. 2014; 41(5): 051702, doi: 10.1118/1.4870376, indexed in Pubmed: 24784368.